Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
There's no extreme hunger, no artificial stimulants, and no need to cut out entire food groups
Sass MR, Klausen MK, Schwarz CR, et al
Type 2 Diabetes Accounts for the Largest Share of the GLP-1 Market Based on the target indication, the market is segmented into Alzheimer's Disease, non-alcoholic steatohepatitis, obesity, sleep apnea, and type 2 diabetes
Many patients experience digestive side effects like nausea, vomiting, stomach pain, or diarrhea when starting standard doses
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment